A Cancer Research UK (CR-UK) Phase Ib Trial to Determine the Safety, Tolerability and Immunogenicity of Extended Schedule Vaccination With MVA-EBNA1/LMP2 in Patients With Epstein Barr Virus Positive (EBV+) Nasopharyngeal Carcinoma (NPC).

Trial Profile

A Cancer Research UK (CR-UK) Phase Ib Trial to Determine the Safety, Tolerability and Immunogenicity of Extended Schedule Vaccination With MVA-EBNA1/LMP2 in Patients With Epstein Barr Virus Positive (EBV+) Nasopharyngeal Carcinoma (NPC).

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Cancer vaccine-EBV (Primary)
  • Indications Epstein-Barr virus infections; Nasopharyngeal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Mar 2013 Planned End Date changed from 31 Mar 2013 to 1 May 2016 as reported by ClinicalTrials.gov.
    • 04 Mar 2013 Planned initiation date (1 Mar 2013) added as reported by ClinicalTrials.gov.
    • 04 Mar 2013 Planned End Date (31 Mar 2013) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top